FDA’s shortage list today
Straight from FDA’s drug shortage database, last updated by FDA in October 2026.
- semaglutide: being discontinued (Rybelsus).
- tirzepatide: not on the list.
- liraglutide: in shortage (Liraglutide, Saxenda, Victoza); being discontinued (Liraglutide, Saxenda).
FDA drug shortage database · read through openFDA · discontinuation is a maker’s decision, not a shortage
In the regulator’s own words
"Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. One month defined as 1 bottle of 30 tablets."
"Whether you self pay or go through insurance, all doses of Wegovy® (semaglutide) and Ozempic® (semaglutide) require a prescription."
"The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily."
This page reports what the regulator has published, in its words. It is not legal or medical advice.